Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SYNACT.ST
STRONG SELLREMOVESynAct Pharma AB · Healthcare · Sweden · $102M · Avg Vol: $577K/d
SynAct Pharma is a Swedish biotech company with high clinical risk and no commercialized products, failing our quality compounder criteria.
COMPANY DESCRIPTION
SynAct Pharma AB is a clinical-stage biotechnology company pioneering selective melanocortin receptor agonists to resolve severe inflammatory and autoimmune diseases. Its lead drug candidate, resatorvid (AP1189), targets the body's natural resolution pathways without suppressing the immune system, offering a novel therapeutic approach. The company operates a lean virtual R&D model, aiming to secure lucrative licensing partnerships with major pharmaceutical firms post-Phase II trials.
FINANCIAL SUMMARY
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — |
| EPS | -0.39 | -0.72 | -0.23 | -0.24 | — |
| Shares | 30M | 36M | 46M | 53M | +78.3% |
| Debt | 224,050 | 69,147 | 204,185 | 131,456 | -16.3% |
| Equity | 14M | 19M | 23M | 18M | 10.4% |
| Op CF | -13M | -11M | -10M | -11M | — |
| Inv CF | 2,931 | 40,164 | 0 | 0 | — |
| Fin CF | 22M | 6M | 9M | 10M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SYNACT.ST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SYNACT.ST | SynAct Pharma AB(you) | $102M | 7 | STRONG SELL |
| XSPRAY.ST | Xspray Pharma AB (publ) | $126M | 5 | STRONG SELL |
| ONCO.ST | Oncopeptides AB (publ) | $76M | 6 | STRONG SELL |
| IBT-B.ST | Infant Bacterial Therapeutics AB (publ) | $82M | 18 | STRONG SELL |
| MVIR.ST | Medivir AB (publ) | $118M | 27 | SELL |
| BINV.ST | BioInvent International AB (publ) | $239M | 20 | STRONG SELL |
| VICO.ST | Vicore Pharma Holding AB (publ) | $356M | 15 | STRONG SELL |
| FLERIE.ST | Flerie AB (publ) | $242M | 23 | SELL |
| EGTX.ST | Egetis Therapeutics AB (publ) | $297M | 22 | SELL |
| GENO.ST | Genovis AB (publ.) | $144M | 48 | HOLD |
Peer medians: ROE 5.1% · P/E 37.9x · Gross margin 62.3%